Predictive value of galectin-1 in the development and progression of HIV-associated lymphoma

MAJA LUDVIGSEN ; RIKKE HJORTEBJERGB ; GITTE PEDERSENE ,; KNUD BENDIXC ; GABRIEL A. RABINOVICH ; IRMA PETRUSKEVICIUSA ; PAUL W. DENTONF ; CARSTEN S. LARSENG ; MAJA ØLHOLM VASE ; STEPHEN H. DUTOITC ; MICHAEL B. MØLLERD ,; BENT HONORE; FRANCESCO D?AMORE

AIDS - AN INTERNATIONAL MONTHLY JOURNAL

LIPPINCOTT WILLIAMS & WILKINS

Lugar: Philadelphia; Año: 2017

0269-9370

At AHIV-1 infection, the binding of the viral envelopeproteins to CD4þ is essential for viral transmission, andthis process is facilitated by interaction with the highlyconserved host lectin, galectin-1 (Gal-1) [1?3]. Withinthe tumor microenvironment, Gal-1 is expressed by bothtumor and stromal cells where it promotes tumorimmune escape and favors hypoxia-driven angiogenesis[4?6]. In sporadically occurring Hodgkin lymphoma,high Gal-1 expression at diagnosis is associated withpoorer treatment response [7], and high soluble Gal-1(sGal-1) correlates with adverse disease characteristics [8].Previous studies have shown that targeted inhibition ofGal-1 prevents tumor-induced immunosuppression[9,10] as well as inhibits tumor growth and metastasisin various tumor models [6,11?13].In conclusion, the results of our study indicate that Gal-1 is significantly associated with risk of lymphoma in HIV-infected individuals and may represent an attractive futuretarget for the management of HIV-associated lymphoma.